Visual Performance Following Implantation of Presbyopia Correcting IOLs

NCT ID: NCT04907955

Last Updated: 2021-06-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-01

Study Completion Date

2020-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the current study was to compare the visual performance after bilateral implantation of the Panoptix IOL , or the AT LISA IOL or Tecnis Symfony IOL . The focus was on intermediate vision, defocus curves, and contrast sensitivity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Loss of Visual Contrast Sensitivity Near Vision Visual Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

panoptix PANFOCAL intraocular lens

panoptix PANFOCAL intraocular lensis a single-piece aspheric non-apodized diffractive panfocal IOL that distributes light energy to three focal points in both small and large pupil conditions

Group Type ACTIVE_COMPARATOR

phacoemulsification with implantation of presbyopia correcting IOL

Intervention Type PROCEDURE

cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL

Trifocal Diffractive the AT LISA intraocular lens

Trifocal Diffractive the AT LISA is a preloaded single-piece aspheric diffractive trifocal IOL and made of hydrophilic acrylic with a hydrophobic surface with an ultraviolet absorber. This aspheric IOL is aberration -correcting in order to reduce and compensate for corneal spherical aberrations.

Group Type ACTIVE_COMPARATOR

phacoemulsification with implantation of presbyopia correcting IOL

Intervention Type PROCEDURE

cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL

Symphony EDOF (extended depth of focus) intraocular lens

SYMPHONY EDOF intraocular lens is a single-piece aspheric biconvex hydrophobic acrylic IOL with a 6.0 mm optic and an 13.0 mm overall diameter. This IOL consists of a wavefront-designed anterior aspheric surface (negative spherical aberration of -0.27 mm to counterbalance the net positive spherical aberration from cornea) and a posterior achromatic diffractive surface with echelette design.

Group Type ACTIVE_COMPARATOR

phacoemulsification with implantation of presbyopia correcting IOL

Intervention Type PROCEDURE

cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

phacoemulsification with implantation of presbyopia correcting IOL

cataract extraction with phacoemulsification and insertion of presbyopia correcting IOL

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with normal ocular examination apart from cataract.

Exclusion Criteria

* previous ocular surgery.
* ocular pathology or corneal abnormalities.
* an endothelial cell count below 2000 cells/mm2.
* corneal astigmatism greater than 1.0 diopter (D) measured with Scheimpflug tomography (Sirius, CSO, Italy).
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dar Al Shifa Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

magda torky

Principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Daralshifa hospital

Kuwait City, , Kuwait

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kuwait

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

02282021065727

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.